Jones Receives NCI Grant
Glioblastoma, the most common type of malignant brain tumor, is a real killer. Most people die within the first two years of diagnosis regardless of the treatments used. With the help of a grant from the National Cancer Institute (NCI), a component of the National Institutes of Health, Terreia Jones, PharmD, assistant professor of Clinical Pharmacy (pictured below), is researching how drugs used to treat glioblastoma change the tumor cells, in hopes of understanding treatment resistance. There are several different cell types that make up these tumors, and all contribute to drug therapy response. The $500,000 grant to the University of Tennessee Health Science Center (UTHSC) supports Dr. Jones' efforts to understand how the drugs used against this disease effect the different cell types that make up the glioblastoma tumors. This work will pave the way to identify new drug targets and treatment approaches for glioblastoma. The NCI grant will be distributed during a four-year period, and is a major milestone for Dr. Jones' brain cancer research program because unlike her past grant awards, this is the first NCI-funded grant she has received. Dr. Jones is an assistant professor at the UTHSC College of Pharmacy and collaborates with brain cancer scientists across the country. "I'm very excited about moving this project forward. We believe that this work will lead to important advances in how brain cancer patients are treated in the future," she said.